Lebrun-Frenay C, Rollot F, Mondot L, Zephir H, Louapre C, Le Page E, et al. Risk factors and time to clinical symptoms of multiple sclerosis among patients with radiologically isolated syndrome. JAMA Netw Open. 2021;4:e2128271.
Lebrun-Frenay C, Okuda DT, Siva A, Landes-Chateau C, Azevedo CJ, Mondot L, et al. The radiologically isolated syndrome: revised diagnostic criteria. Brain. 2023;146:3431–43.
Okuda DT, Siva A, Kantarci O, Inglese M, Katz I, Tutuncu M, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One. 2014;9:e90509.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73.
Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72:800–5.
Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011;76:686–92.
Montalban X. 2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis [Video]. In: Presented at ECTRIMS Congress in Copenhagen. Scientific Session 1: New Diagnostic Criteria. Copenhagen, Denmark: ECTRIMS; 2024. Available from: https://www.neurologylive.com/view/2024-revisions-mcdonald-diagnostic-criteria-multiple-sclerosis-peter-calabresi.
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. 2015;21:1013–24.
Lebrun-Frenay C, Siva A, Sormani MP, Landes-Chateau C, Mondot L, Bovis F, et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical trial. JAMA Neurol. 2023;80:1080–8.
Okuda DT, Kantarci O, Lebrun-Frenay C, Sormani MP, Azevedo CJ, Bovis F, et al. Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann Neurol. 2023;93:604–14.
Okuda DT, Azevedo CJ, Pelletier D, Moog TM, Moazami S, Rezvani S, et al. Dimethyl fumarate preserves brainstem and cervical spinal cord integrity in radiologically isolated syndrome. J Neurol. 2024;271:5899–910.
Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977–86.
Longbrake EE, Cross AH, Salter A. Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice. Mult Scler J Exp Transl Clin. 2016;2:2055217316677868.
Lebrun-Frenay C, Kantarci O, Siva A, Sormani MP, Pelletier D, Okuda DT, et al. Radiologically isolated syndrome: 10-year risk estimate of a clinical event. Ann Neurol. 2020;88:407–17.
Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84:909–14.
Rival M, Galoppin M, Thouvenot E. Biological markers in early multiple sclerosis: the paved way for radiologically isolated syndrome. Front Immunol. 2022;13:866092.
Bielekova B, Pranzatelli MR. Promise, progress, and pitfalls in the search for central nervous system biomarkers in neuroimmunological diseases: a role for cerebrospinal fluid immunophenotyping. Semin Pediatr Neurol. 2017;24:229–39.
Zamecnik CR, Sowa GM, Abdelhak A, Dandekar R, Bair RD, Wade KJ, et al. An autoantibody signature predictive for multiple sclerosis. Nat Med. 2024;30:1300–8.
Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375:296–301.
Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15:160–71.
Ligocki AJ, Rounds WH, Cameron EM, Harp CT, Frohman EM, Courtney AM, et al. Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation. Genes Immun. 2013;14:291–301.
Rivas JR, Ireland SJ, Chkheidze R, Rounds WH, Lim J, Johnson J, et al. Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients. Acta Neuropathol. 2017;133:43–60.
Ligocki AJ, Rivas JR, Rounds WH, Guzman AA, Li M, Spadaro M, et al. A distinct class of antibodies may be an indicator of gray matter autoimmunity in early and established relapsing remitting multiple sclerosis patients. ASN Neuro. 2015;7:1759091415609613.
Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain. 2005;128:1667–76.
Bogers L, Engelenburg HJ, Janssen M, Unger PA, Melief MJ, Wierenga-Wolf AF, et al. Selective emergence of antibody-secreting cells in the multiple sclerosis brain. EBioMedicine. 2023;89:104465.
Telesford KM, Smith C, Mettlen M, Davis MB, Cowell L, Kittles R, et al. Neuron-binding antibody responses are associated with Black ethnicity in multiple sclerosis during natalizumab treatment. Brain Commun. 2023;5:fcad218.
Bennett JL, Haubold K, Ritchie AM, Edwards SJ, Burgoon M, Shearer AJ, et al. CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. J Neuroimmunol. 2008;199:126–32.
Owens GP, Winges KM, Ritchie AM, Edwards S, Burgoon MP, Lehnhoff L, et al. VH4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J Immunol. 2007;179:6343–51.
Owens GP, Kraus H, Burgoon MP, Smith-Jensen T, Devlin M E, Gilden DH. Restricted use of VH4 germline segments in an acute multiple sclerosis brain. Ann Neurol. 1998;43:236–43.
Zhang W, Joshi C, Smith C, Ujas TA, Rivas JR, Cowell L, et al. Neuronal binding by antibodies can be influenced by low pH stress during the isolation procedure. J Immunol Methods. 2023;521:113535.
von Budingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, et al. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest. 2012;122:4533–43.
Estrada K, Whelan CW, Zhao F, Bronson P, Handsaker RE, Sun C, et al. A whole-genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun. 2018;9:1929.
Li J, Bazzi SA, Schmitz F, Tanno H, McDaniel JR, Lee CH, et al. Molecular level characterization of circulating aquaporin-4 antibodies in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1034.
Smith C, Telesford KM, Piccirillo SGM, Licon-Munoz Y, Zhang W, Tse KM, et al. Astrocytic stress response is induced by exposure to astrocyte-binding antibodies expressed by plasmablasts from pediatric patients with acute transverse myelitis. J Neuroinflammation. 2024;21:161.
Monson NL, Ireland SJ, Ligocki AJ, Chen D, Rounds WH, Li M, et al. Elevated CNS inflammation in patients with preclinical Alzheimer’s disease. J Cereb Blood Flow Metab. 2014;34:30–3.
Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A, et al. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69:305–8.
Rosenfeld AM, Meng W, Chen DY, Zhang B, Granot T, Farber DL, et al. Computational evaluation of B-cell clone sizes in bulk populations. Front Immunol. 2018;9:1472.
Christley S, Scarborough W, Salinas E, Rounds WH, Toby IT, Fonner JM, et al. VDJServer: a cloud-based analysis portal and data commons for immune repertoire sequences and rearrangements. Front Immunol. 2018;9:976.
Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 2013;41:W34–40.
Gupta NT, Vander Heiden JA, Uduman M, Gadala-Maria D, Yaari G, Kleinstein SH. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics. 2015;31:3356–8.
Zar JH. Biostatistical analysis, 5th ed. Upper Saddle River, NJ: Prentice Hall/Pearson; 2010. p. 644.
Cameron EM, Spencer S, Lazarini J, Harp CT, Ward ES, Burgoon M, et al. Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. J Neuroimmunol. 2009;213:123–30.
Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods. 2008;329:112–24.
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–82.
Kohsaka H, Carson DA, Rassenti LZ, Ollier WE, Chen PP, Kipps TJ, et al. The human immunoglobulin V(H) gene repertoire is genetically controlled and unaltered by chronic autoimmune stimulation. J Clin Invest. 1996;98:2794–800.
Boziki M, Bakirtzis C, Sintila SA, Kesidou E, Gounari E, Ioakimidou A, et al. Ocrelizumab in patients with active primary progressive multiple sclerosis: clinical outcomes and immune markers of treatment response. Cells. 2022;11:1959.
Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kumpfel T, et al. Association of intrathecal immunoglobulin G synthesis with disability worsening in multiple sclerosis. JAMA Neurol. 2019;76:841–9.
Kinnunen T, Chamberlain N, Morbach H, Cantaert T, Lynch M, Preston-Hurlburt P, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. 2013;123:2737–41.
Telesford KM, Kaunzner UW, Perumal J, Gauthier SA, Wu X, Diaz I, et al. Black African and Latino/a identity correlates with increased plasmablasts in MS. Neurol Neuroimmunol Neuroinflamm. 2020;7:e634.
Kreiter D, Postma AA, Hupperts R, Gerlach O. Hallmarks of spinal cord pathology in multiple sclerosis. J Neurol Sci. 2024;456:122846.
Bot JC, Barkhof F, Polman CH, Lycklama A, Nijeholt GJ, de Groot V, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology. 2004;62:226–33.
Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, et al. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology. 2013;80:69–75.
Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castillo J, Rio J, et al. Spinal cord lesions: a modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult Scler. 2018;24:301–12.
Guerrier T, Labalette M, Launay D, Lee-Chang C, Outteryck O, Lefevre G, et al. Proinflammatory B-cell profile in the early phases of MS predicts an active disease. Neurol Neuroimmunol Neuroinflamm. 2018;5:e431.
Schickel JN, Glauzy S, Ng YS, Chamberlain N, Massad C, Isnardi I, et al. Self-reactive VH4-34-expressing IgG B cells recognize commensal bacteria. J Exp Med. 2017;214:1991–2003.
Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest. 2001;108:1061–70.
Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol. 1999;163:5133–44.
Liu Y, Given KS, Harlow DE, Matschulat AM, Macklin WB, Bennett JL, et al. Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination. Acta Neuropathol Commun. 2017;5:25.
Peschl P, Schanda K, Zeka B, Given K, Bohm D, Ruprecht K, et al. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation. 2017;14:208.
Hoftberger R, Lassmann H, Berger T, Reindl M. Pathogenic autoantibodies in multiple sclerosis – from a simple idea to a complex concept. Nat Rev Neurol. 2022;18:681–8.
Sechi E, Flanagan EP. Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management. Front Neurol. 2021;12:673339.
Racanelli V, Prete M, Musaraj G, Dammacco F, Perosa F. Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev. 2011;10:503–8.
Salapa HE, Thibault PA, Libner CD, Ding Y, Clarke JWE, Denomy C, et al. hnRNP A1 dysfunction alters RNA splicing and drives neurodegeneration in multiple sclerosis (MS). Nat Commun. 2024;15:356.
Paliwal S, Thakkar D, Chin WJ, Lee W, Neo JJY, Tay L, et al. Selective targeting of pathogenic auto-reactive VH4–34 B cells with a rationally developed anti-VH4–34 antibody offers a new therapeutic approach for autoimmune disorders. J Immunol. 2023;210:238.20–20.
Janigro D, Bailey DM, Lehmann S, Badaut J, O’Flynn R, Hirtz C, et al. Peripheral Blood and Salivary Biomarkers of Blood-Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts. Front Neurol. 2020;11:577312.
Takata F, Nakagawa S, Matsumoto J, Dohgu S. Blood-Brain Barrier Dysfunction Amplifies the Development of Neuroinflammation: Understanding of Cellular Events in Brain Microvascular Endothelial Cells for Prevention and Treatment of BBB Dysfunction. Front Cell Neurosci. 2021;15:661838.
Merlini M, Sozmen EG, Subramanian KS, Nana AL, Seeley WW, Akassoglou K. Three-Dimensional Imaging of Fibrinogen and Neurovascular Alterations in Alzheimer’s Disease. Methods Mol Biol. 2023;2561:87–101.